Nicox NCX 470 Shows Retinal Cell Protection in Non-clinical Model
September 29, 2021 – release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today published new data on NCX 470 in a non-clinical model of endothelin-1 (ET-1) -induced retinal cell damage . Nicox’s lead clinical candidate NCX 470 is a nitric oxide donor prostaglandin analogue currently in phase 3 clinical development for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Elevated IOP is the primary risk factor for glaucoma, however a variety of independent risk factors for IOP, including ischemia, contribute to damage to the optic nerve head and retina, ultimately causing vision loss. The exploratory non-clinical studies reported today investigated the potential protective effects of NCX 470 on the retina and optic nerve head. The results suggest that NCX 470 improves ocular perfusion and retinal function of damaged eyes compared to vehicle and therefore may have therapeutic properties beyond lowering IOP.
To study Design and Rresults
Nonclinical experiments were performed to determine the effect of NCX 470 on ocular vascular reactivity and retinal function after repeated topical ocular administration in a well-defined model of ET-induced ischemia / reperfusion optic nerve injury in rabbits. -1. ET-1 alone was administered twice weekly for two weeks, followed by concomitant administration of NCX 470 or vehicle for an additional 4 weeks.
Bi-weekly administration of ET-1 increased ophthalmic artery resistivity after two weeks (p
Additionally, ET-1 assay resulted in a marked decrease in photoreceptor responses, which continued in vehicle-treated eyes. The decline was almost completely reversed at week 6 in eyes treated with NCX 470 (p
About the NCX 470
NCX 470 is a new, potentially best-in-class, nitric oxide (NO) donor prostaglandin analog monotherapy in development to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or glaucoma. ocular hypertension. Glaucoma is a group of eye diseases in which the optic nerve is damaged, resulting in loss of the peripheral and ultimately central visual field and possibly leading to blindness if left untreated. It is commonly linked to abnormally high IOP (around 90% of patients) due to a blockage or malfunction of the eye’s aqueous humor drainage system at the front of the eye. In 2020, global sales of treatments targeting glaucoma exceeded $ 6.0 billion in a $ 24.3 billion global market for ophthalmic drugs.
NCX 470 is designed to release both bimatoprost and NO after instillation into the eye. Bimatoprost, marketed under the brand name LUMIGANÂ® by Allergan, Inc., is a leading product in the prostaglandin analog class, the class of drugs most widely used to lower IOP in patients with glaucoma. open angle or ocular hypertension.
Nicox SA is an international ophthalmology company that develops innovative solutions to help maintain vision and improve eye health. Nicox’s primary clinical development program is NCX 470, a novel nitric oxide donor prostaglandin analogue for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates income from VYZULTAÂ® in glaucoma, licensed exclusively worldwide to Bausch + Lomb and ZERVIATEÂ® in allergic conjunctivitis, licensed in several geographies, including Eyevance Pharmaceuticals, LLC, in the United States and Ocumension Therapeutics in China and the majority of Southeast Asian markets.
Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indices.
For more information about Nicox, its products or its pipeline, please visit: www.nicox.com.
Bryan, Garnier & Co Victor Floc’h Paris, France
Cantor Fitzgerald Louise Chen New York, United States
Edison Investment Research Pooya Hemami London, United Kingdom
HC Wainwright & Co Yi Chen New York, United States
Kepler Cheuvreux Damien Choplain Paris, France
The opinions expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. In addition, the information in their reports may not be correct or up to date. Nicox disclaims any obligation to correct or update information contained in analyst reports.
Executive Vice-President, Chief Business Officer
& Head of business development
T +33 (0) 4 97 24 53 00
Investors and media
United States and Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
LifeSci Advisors, LLC
T +33 (0) 6 27 74 74 49
The information contained in this document is subject to change without notice. This information includes forward-looking statements. These forward-looking statements are not guarantees of future performance. These statements are based on the current expectations or beliefs of Nicox SA management and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, advisers or agents, do not undertake and have no obligation to provide updates or revise forward-looking statements.
The risk factors likely to have a significant effect on Nicox’s activity are presented in the 3rd chapter of the ‘Universal registration document, annual financial report and management report 2020‘deposited with the French Financial Markets Authority (AMF) as of March 1, 2021 available on the Nicox website (www.nicox.com).
Building D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0) 4 97 24 53 00
F +33 (0) 4 97 24 53 99